Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
Oxford, UK – May 9, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced expanded access to Axumin® (fluciclovine (18F)) in Europe. The first commercial...
Read More ›– Results related to Company’s investigational radiohybrid PSMA acquisition presented at AUA2019 – BURLINGTON, Mass. and OXFORD, UK, May 6, 2019 – Blue Earth Diagnostics, a molecular imaging diagnostics...
Read More ›– Presentations at AUA2019 explore Axumin detection rate and relationship to PSA levels, based on extent of recurrence and prior treatment – BURLINGTON, Mass. and OXFORD, UK, May 6,...
Read More ›BURLINGTON, Mass. and OXFORD, UK, April 24, 2019 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced upcoming presentations at the American Urological Association’s 2019 Annual Meeting,...
Read More ›